Loading...
OTCMRTSL
Market cap26kUSD
Nov 08, Last price  
0.00USD
Name

Rapid Therapeutic Science Laboratories Inc

Chart & Performance

D1W1MN
OTCM:RTSL chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
134.87%
Rev. gr., 5y
%
Revenues
0k
-100.00%
000009,1395340
Net income
-2m
L-59.65%
-18,957-12,303-12,020-21,616-2,552,914-348,841-4,197,324-1,693,802
CFO
-1m
L-47.87%
-20,000-13,434-8,576-10,743-21,843-129,854-106,663-2,209,131-1,151,709

Profile

Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. The company engages in the aerosol delivery of non-psychoactive cannabinoids to the blood stream for treatment of chronic pain, post-traumatic stress disorder, insomnia, surgery recovery, and other ailments. It offers pressurized meter dose inhaler, a device that delivers a measured amount of aerosolized inhalant in a mist to the lungs; sublingual oral spray devices; and water-soluble cannabidiol and cannabigerol isolates under the nhaler brand. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc.
IPO date
Oct 31, 2013
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑032018‑032017‑032016‑032015‑03
Income
Revenues
534
-94.16%
Cost of revenue
1,239
2,115
Unusual Expense (Income)
NOPBT
(1,239)
(2,114)
NOPBT Margin
Operating Taxes
(101)
1,329
Tax Rate
NOPAT
(1,138)
(3,444)
Net income
(1,694)
-59.65%
(4,197)
1,103.22%
Dividends
Dividend yield
Proceeds from repurchase of equity
585
BB yield
-30.67%
Debt
Debt current
3,400
1,457
Long-term debt
809
981
Deferred revenue
Other long-term liabilities
Net debt
4,588
2,245
Cash flow
Cash from operating activities
(1,152)
(2,209)
CAPEX
(39)
(293)
Cash from investing activities
(39)
(293)
Cash from financing activities
998
2,195
FCF
(1,224)
(4,099)
Balance
Cash
(379)
192
Long term investments
Excess cash
192
Stockholders' equity
(10,308)
(8,328)
Invested Capital
10,998
8,932
ROIC
ROCE
EV
Common stock shares outstanding
7,747
7,630
Price
0.75
200.00%
0.25
 
Market cap
5,810
204.62%
1,907
 
EV
10,398
4,152
EBITDA
(1,215)
(2,059)
EV/EBITDA
Interest
1,896
1,329
Interest/NOPBT